Tag: cfDNA

Donor-derived cell-free DNA as a composite marker of acute lung allograft dysfunction in clinical care

This article was originally published here J Heart Lung Transplant. 2021 Dec 26:S1053-2498(21)02630-9. doi: 10.1016/j.healun.2021.12.009. Online ahead of print. ABSTRACT BACKGROUND: As a marker of underlying lung allograft injury, donor-derived cell-free DNA (dd-cfDNA) may be used to identify episodes of acute allograft injury in lung transplant recipients. We investigated the…

Continue Reading Donor-derived cell-free DNA as a composite marker of acute lung allograft dysfunction in clinical care

Why a huge NHS unit is on Nuneaton’s Asda car park

A huge NHS unit is on Nuneaton’s Asda car park as a trail-blazing trial of a new cancer-detecting blood test is under way. As we reported in our newsletter, the town was just one of a handful of areas across the Midlands to be picked as part of the pilot….

Continue Reading Why a huge NHS unit is on Nuneaton’s Asda car park

Cell-free DNA for the detection of emerging treatment failure in relapsed/ refractory multiple myeloma

Interrogation of cell-free DNA (cfDNA) represents an emerging approach to non-invasively estimate disease burden in multiple myeloma (MM). Here, we examined low-pass whole genome sequencing (LPWGS) of cfDNA for its predictive value in relapsed/ refractory MM (RRMM). We observed that cfDNA positivity, defined as ≥10% tumor fraction by LPWGS, was…

Continue Reading Cell-free DNA for the detection of emerging treatment failure in relapsed/ refractory multiple myeloma

NIH Study Shows Using CareDx’s AlloSure Lung for Transplant Surveillance is More Effective than Diagnostic Bronchoscopy at Identifying Rejection

SOUTH SAN FRANCISCO, Calif., Jan. 07, 2022 (GLOBE NEWSWIRE) — CareDx, Inc.,  (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the results of a study led by the National Institutes of…

Continue Reading NIH Study Shows Using CareDx’s AlloSure Lung for Transplant Surveillance is More Effective than Diagnostic Bronchoscopy at Identifying Rejection

Genome-wide cfDNA screening: clinical laboratory experience with the first 10,000 cases

doi.org/10.1038/gim.2017.56Get rights and content Abstract Purpose Invasive diagnostic prenatal testing can provide the most comprehensive information about the genetic status of a fetus. Noninvasive prenatal screening methods, especially when using cell-free DNA (cfDNA), are often limited to reporting only on trisomies 21, 18, and 13 and sex chromosome aneuploidies. This…

Continue Reading Genome-wide cfDNA screening: clinical laboratory experience with the first 10,000 cases

cfDNA ultra-deep sequencing with UMIs

cfDNA ultra-deep sequencing with UMIs 1 Dear all, I am analyzing sequencing data from a capture panel which uses UMIs. I did ultra-deep sequencing to detect variants in a very low VAF (less than 1%). This is an already fragmented DNA coming from plasma. After doing my pipeline using fgbio,…

Continue Reading cfDNA ultra-deep sequencing with UMIs

QIAseq cfDNA Library Kit, 96 reactions

QIAseq cfDNA Library Kit, 96 reactions   For 96 reactions on Illumina® sequencers: enzymes and buffers for cfDNA library prep, Illumina Adapter Plate 96-plex, Illumina Library Amplification Primer and PCR Master Mix   Features • Optimal conversion of cfDNA at every step from plasma to NGS library through highly efficient…

Continue Reading QIAseq cfDNA Library Kit, 96 reactions

Natera launches Prospera with quantification to improve kidney graft rejection testing

Natera has announced the launch of Prospera with quantification, the only cell-free DNA (cfDNA) test for kidney rejection that provides three values—the quantity of donor-derived cfDNA (dd-cfDNA), fraction of dd-cfDNA, and total cfDNA—on every report. Combining these three metrics has been shown to improve sensitivity when evaluating transplant rejection, compared…

Continue Reading Natera launches Prospera with quantification to improve kidney graft rejection testing

Liquid Biopsy Noninferior to Tissue-Based Genotyping in Management of Advanced NSCLC

Cell-free circulating tumor DNA (cfDNA)–based tumor genotyping was found to be noninferior to standard-of-care tissue-based genotyping for detection of guideline-recommended biomarkers and therapeutic outcomes in patients with advanced nonsquamous non–small cell lung cancer (NSCLC). Cell-free circulating tumor DNA (cfDNA)–based tumor genotyping is noninferior to tissue-based genotyping for detection of guideline-recommended…

Continue Reading Liquid Biopsy Noninferior to Tissue-Based Genotyping in Management of Advanced NSCLC

Scientist, Bioinformatics – Leonia | Mendeley Careers

We’re hiring Bioinformatics Scientists with strong backgrounds in database development, management and analysis as they relate to human health and disease biomarkers, with the goal of improving disease prediction and prevention. With ICR, you’ll get to: Design, build, test and refine multiple large biomarker databases in collaboration with multiple ICR…

Continue Reading Scientist, Bioinformatics – Leonia | Mendeley Careers

Reliability of Cell-Free DNA (cfDNA) Next Generation Sequencing in Predicting Chromosomal Structural Abnormalities and Cytogenetic-Risk Stratification of Patients with Myeloid Neoplasms

Oral and Poster Abstracts 617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster III Translational Research Maher Albitar, MD1*, Andrew Ip, MD, MSc2, Andre H. Goy, MD3*, Jeffrey Justin Estella, BS, MS1*, Ivan De Dios, BS1*,…

Continue Reading Reliability of Cell-Free DNA (cfDNA) Next Generation Sequencing in Predicting Chromosomal Structural Abnormalities and Cytogenetic-Risk Stratification of Patients with Myeloid Neoplasms

PNAS Papers on Long Cell-Free DNA in Maternal Plasma, Genetic Propensity for Voting

The discovery of a large population of long, cell-free DNA (cfDNA) molecules in maternal plasma, along with a method to identify the molecules’ tissues of origin, is reported in this week Proceedings of the National Academy of Sciences. To date, studies of circulating cfDNA have focused on short molecules of…

Continue Reading PNAS Papers on Long Cell-Free DNA in Maternal Plasma, Genetic Propensity for Voting

What is the Liquid Biopsy, How’s it provided, and what is the Role of the Pulmonologist?

Non–small cell lung carcinoma is the most prevalent kind of lung cancer, and it is also the disease that causes the most fatalities globally each year. The liquid biopsy is the most recent step forward in personalized medicine in cancer therapy, allowing treatment depending on driver mutations found within a…

Continue Reading What is the Liquid Biopsy, How’s it provided, and what is the Role of the Pulmonologist?

Clinical Limit of Detection May Represent Viable cfDNA Metric For Detection of Multiple Cancers

Data were taken from a prospective, multi-center, observational study (NCT02889978), which evaluated cell-free DNA multi-omics in prototype cfDNA-based multi-cancer early detection tests. In the study, researchers collected plasma and matched white blood cells before sequencing them from CCGA study participants (n = 2,800). Tumor biopsies were also sequenced when available….

Continue Reading Clinical Limit of Detection May Represent Viable cfDNA Metric For Detection of Multiple Cancers

cLOD May Provide More Accurate Evaluation of Cell-Free DNA in Multi-Cancer Early Detection

Clinical limit of detection may be a reasonable metric for evaluating cell-free DNA for multi-cancer early detection. Clinical limit of detection (cLOD) may be a reasonable metric for evaluating cell-free DNA (cfDNA) for multi-cancer early detection, according to recent data from the Circulating Cell-Free Genome Atlas (CCGA) study (NCT02889978). In…

Continue Reading cLOD May Provide More Accurate Evaluation of Cell-Free DNA in Multi-Cancer Early Detection

BioSpace hiring Scientist, Bioinformatics in Leonia, New Jersey, United States

We’re hiringBioinformatics Scientists with strong backgrounds in database development, management and analysis as they relate to human health and disease biomarkers, with the goal of improving disease prediction and prevention. With ICR, You’ll Get To Design, build, test and refine multiple large biomarker databases in collaboration with multiple ICR teams…

Continue Reading BioSpace hiring Scientist, Bioinformatics in Leonia, New Jersey, United States

Senior Bioinformatics Engineer | United States

Natera™ is a global leader in cell-free DNA (cfDNA) testing with a focus on women’s health, oncology, and organ health. To bolster our oncology products, we are looking for a Senior Bioinformatics Engineer to provide technical leadership and process guidance. Through collaboration between the product and development teams, the Senior…

Continue Reading Senior Bioinformatics Engineer | United States

New publication in European Urology demonstrates value of PredicineCARE liquid biopsy test for monitoring PD-L1 immunotherapy in patients with metastatic prostate cancer | News

HAYWARD, Calif., Sept. 16, 2021 /PRNewswire-PRWeb/ — Predicine, Inc. announced today results from a liquid biopsy study demonstrating the clinical application of utilizing the PredicineCARE liquid biopsy NGS assay to serially monitor changes in ctDNA levels in patients with metastatic castration-resistant prostate cancer (mCRPC). The European Urology study evaluated the effects…

Continue Reading New publication in European Urology demonstrates value of PredicineCARE liquid biopsy test for monitoring PD-L1 immunotherapy in patients with metastatic prostate cancer | News

The Current Molecular Treatment Landscape of Advanced Colorectal Cancer and Need for the COLOMATE Platform

Next-Generation Sequencing Utilizing Tumor Tissue and/or Blood The identification of actionable genomic alterations in tumors such as mCRC was once performed by Sanger DNA sequencing of tumor DNA that was extracted from fixed paraffin-embedded tumor tissue, but this has now been replaced by next-generation sequencing (NGS), which allows for larger-scale…

Continue Reading The Current Molecular Treatment Landscape of Advanced Colorectal Cancer and Need for the COLOMATE Platform

Novel Test Distinguishes Benign From Malignant Lesions in NF1

A novel liquid biopsy test has been shown to distinguish between patients with neurofibromatosis type 1 (NF1) who have benign plexiform neurofibroma (PN) precursor lesions from patients who have malignant peripheral nerve sheath tumors (MPNST), say authors of a multi-institutional cross-sectional study. “Transformation from PN to MPNST is challenging to…

Continue Reading Novel Test Distinguishes Benign From Malignant Lesions in NF1

Science Papers Uncover Protein Involved in Tumor Metastasis, Cancer Detection Via DNA Methylation Sequencing

Using a temporal multi-omics approach, a team led by scientists from Heidelberg University has identified a protein involved in tumor metastasis that could serve as a new therapeutic cancer target. Metastasis is the leading cause of cancer-related mortality and the mechanistically least well-understood step of the tumor progression cascade. However,…

Continue Reading Science Papers Uncover Protein Involved in Tumor Metastasis, Cancer Detection Via DNA Methylation Sequencing

Bioinformatics Engineer | San Carlos, CA

Date posted: Aug 28, 2021 Natera™ is a global leader in cell-free DNA (cfDNA) testing with a focus on women’s health, oncology, and organ health. To bolster our oncology solutions, we are looking for a Bioinformatics Engineer to provide analytical and data management support for Natera’s oncology product. The Bioinformatics…

Continue Reading Bioinformatics Engineer | San Carlos, CA

AI Blood Test Shown to Detect >90% of Lung Cancers Across Different Stages

A novel artificial intelligence (AI) blood testing technology developed by researchers at the Johns Hopkins Kimmel Cancer Center has been shown to detect over 90% of lung cancers in samples from nearly 800 individuals with and without cancer. The test approach, called DELFI (DNA evaluation of fragments for early interception), spots unique…

Continue Reading AI Blood Test Shown to Detect >90% of Lung Cancers Across Different Stages

Thermo Fisher Scientific hiring Bioinformatics Scientist in South San Francisco, California, United States

Job Title; Bioinformatics Scientist, DNA Sequencing Position Location: South San Francisco, CA As a bioinformatics scientist / engineer developing applications in oncology, personalized medicine, inherited disease, and viral/microbial genetics, you will play a key role in developing, improving, and expanding analysis solutions for next-generation DNA sequencing products. Primary responsibilities will…

Continue Reading Thermo Fisher Scientific hiring Bioinformatics Scientist in South San Francisco, California, United States